{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T16:33:18Z","timestamp":1792168398725,"version":"4.4.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,6,23]],"date-time":"2010-06-23T00:00:00Z","timestamp":1277251200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1186\/1471-2334-10-183","type":"journal-article","created":{"date-parts":[[2010,6,23]],"date-time":"2010-06-23T18:13:59Z","timestamp":1277316839000},"source":"Crossref","is-referenced-by-count":49,"title":["The efficacy and safety of insulin-sensitizing drugs in HIV-associated lipodystrophy syndrome: a meta-analysis of randomized trials"],"prefix":"10.1186","volume":"10","author":[{"given":"Siddharth H","family":"Sheth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin J","family":"Larson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,6,23]]},"reference":[{"issue":"Suppl 2","key":"1163_CR1","first-page":"23S","volume":"118","author":"SK Grinspoon","year":"2005","unstructured":"Grinspoon SK: Metabolic syndrome and cardiovascular disease in patients with human immunodeficiency virus. American Journal of Medicine. 2005, 118 (Suppl 2): 23S-28S.","journal-title":"American Journal of Medicine"},{"issue":"6","key":"1163_CR2","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1086\/317477","volume":"31","author":"R Thiebaut","year":"2000","unstructured":"Thiebaut R, Daucourt V, Mercie P, Ekouevi DK, Malvy D, Morlat P, Dupon M, Neau D, Farbos S, Marimoutou C, et al: Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999. Groupe d'Epidemiologie Clinique du Syndrome d'Immunodeficience Acquise en Aquitaine. Clinical Infectious Diseases. 2000, 31 (6): 1482-1487. 10.1086\/317477.","journal-title":"Clinical Infectious Diseases"},{"issue":"4","key":"1163_CR3","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1007\/s11136-004-2580-2","volume":"14","author":"R Burgoyne","year":"2005","unstructured":"Burgoyne R, Collins E, Wagner C, Abbey S, Halman M, Nur M, Walmsley S: The relationship between lipodystrophy-associated body changes and measures of quality of life and mental health for HIV-positive adults. Quality of Life Research. 2005, 14 (4): 981-990. 10.1007\/s11136-004-2580-2.","journal-title":"Quality of Life Research"},{"issue":"18","key":"1163_CR4","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1097\/00002030-200112070-00012","volume":"15","author":"S Duran","year":"2001","unstructured":"Duran S, Saves M, Spire B, Cailleton V, Sobel A, Carrieri P, Salmon D, Moatti JP, Leport C, Group AS: Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy. AIDS. 2001, 15 (18): 2441-2444. 10.1097\/00002030-200112070-00012.","journal-title":"AIDS"},{"issue":"1","key":"1163_CR5","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1097\/01.qai.0000159323.59250.83","volume":"39","author":"SE Dolan","year":"2005","unstructured":"Dolan SE, Hadigan C, Killilea KM, Sullivan MP, Hemphill L, Lees RS, Schoenfeld D, Grinspoon S: Increased cardiovascular disease risk indices in HIV-infected women. Journal of Acquired Immune Deficiency Syndromes: JAIDS. 2005, 39 (1): 44-54. 10.1097\/01.qai.0000159323.59250.83.","journal-title":"Journal of Acquired Immune Deficiency Syndromes: JAIDS"},{"issue":"7","key":"1163_CR6","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1086\/368185","volume":"36","author":"C Hadigan","year":"2003","unstructured":"Hadigan C, Meigs JB, Wilson PWF, D'Agostino RB, Davis B, Basgoz N, Sax PE, Grinspoon S: Prediction of coronary heart disease risk in HIV-infected patients with fat redistribution. Clinical Infectious Diseases. 2003, 36 (7): 909-916. 10.1086\/368185.","journal-title":"Clinical Infectious Diseases"},{"issue":"15","key":"1163_CR7","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.2165\/00003495-200666150-00006","volume":"66","author":"BM Bergersen","year":"2006","unstructured":"Bergersen BM: Cardiovascular risk in patients with HIV Infection: impact of antiretroviral therapy. Drugs. 2006, 66 (15): 1971-1987. 10.2165\/00003495-200666150-00006.","journal-title":"Drugs"},{"issue":"21","key":"1163_CR8","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1056\/NEJMoa030218","volume":"349","author":"The Data Collection on Adverse Events of Anti HIVDSG","year":"2003","unstructured":"The Data Collection on Adverse Events of Anti HIVDSG: Combination Antiretroviral Therapy and the Risk of Myocardial Infarction. N Engl J Med. 2003, 349 (21): 1993-2003. 10.1056\/NEJMoa030218.","journal-title":"N Engl J Med"},{"issue":"17","key":"1163_CR9","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa062744","volume":"356","author":"N Friis-Moller","year":"2007","unstructured":"Group DADS, Friis-Moller N, Reiss P, Sabin CA, Weber R, Monforte AdA, El-Sadr W, Thiebaut R, De Wit S, Kirk O: Class of antiretroviral drugs and the risk of myocardial infarction.[see comment]. New England Journal of Medicine. 2007, 356 (17): 1723-1735. 10.1056\/NEJMoa062744.","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"1163_CR10","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1056\/NEJMra041811","volume":"352","author":"S Grinspoon","year":"2005","unstructured":"Grinspoon S, Carr A: Cardiovascular Risk and Body-Fat Abnormalities in HIV-Infected Adults. New England Journal of Medicine. 2005, 352 (1): 48-10.1056\/NEJMra041811.","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"1163_CR11","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1080\/00365540410019381","volume":"36","author":"BR Hansen","year":"2004","unstructured":"Hansen BR, Haugaard SB, Iversen J, Nielsen JO, Andersen O: Impact of switching antiretroviral therapy on lipodystrophy and other metabolic complications: a review. Scandinavian Journal of Infectious Diseases. 2004, 36 (4): 244-253. 10.1080\/00365540410019381.","journal-title":"Scandinavian Journal of Infectious Diseases"},{"issue":"2","key":"1163_CR12","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1001\/jama.288.2.207","volume":"288","author":"A Carr","year":"2002","unstructured":"Carr A, Workman C, Smith DE, Hoy J, Hudson J, Doong N, Martin A, Amin J, Freund J, Law M, et al: Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial.[see comment]. JAMA. 2002, 288 (2): 207-215. 10.1001\/jama.288.2.207.","journal-title":"JAMA"},{"issue":"16","key":"1163_CR13","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1097\/01.aids.0000247574.33998.03","volume":"20","author":"GJ Moyle","year":"2006","unstructured":"Moyle GJ, Sabin CA, Cartledge J, Johnson M, Wilkins E, Churchill D, Hay P, Fakoya A, Murphy M, Scullard G, et al: A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS. 2006, 20 (16): 2043-2050. 10.1097\/01.aids.0000247574.33998.03.","journal-title":"AIDS"},{"issue":"6","key":"1163_CR14","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1111\/j.1742-1241.2007.01385.x","volume":"61","author":"L Waters","year":"2007","unstructured":"Waters L, Nelson M: Long-term complications of antiretroviral therapy: lipoatrophy. International Journal of Clinical Practice. 2007, 61 (6): 999-1014. 10.1111\/j.1742-1241.2007.01385.x.","journal-title":"International Journal of Clinical Practice"},{"issue":"10","key":"1163_CR15","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1086\/343050","volume":"35","author":"H Drechsler","year":"2002","unstructured":"Drechsler H, Powderly WG: Switching Effective Antiretroviral Therapy: A Review. Clinical Infectious Diseases. 2002, 35 (10): 1219-1230. 10.1086\/343050.","journal-title":"Clinical Infectious Diseases"},{"issue":"18","key":"1163_CR16","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.2165\/00003495-200767180-00008","volume":"67","author":"ED Deeks","year":"2007","unstructured":"Deeks ED, Keam SJ: Rosiglitazone: a review of its use in type 2 diabetes mellitus. Drugs. 2007, 67 (18): 2747-2779. 10.2165\/00003495-200767180-00008.","journal-title":"Drugs"},{"issue":"1","key":"1163_CR17","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/S0002-9343(01)00713-6","volume":"111","author":"MS Kipnes","year":"2001","unstructured":"Kipnes MS, Krosnick A, Rendell MS, Egan JW, Mathisen AL, Schneider RL: Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. The American Journal of Medicine. 2001, 111 (1): 10-17. 10.1016\/S0002-9343(01)00713-6.","journal-title":"The American Journal of Medicine"},{"issue":"8","key":"1163_CR18","doi-asserted-by":"publisher","first-page":"611","DOI":"10.7326\/0003-4819-142-8-200504190-00009","volume":"142","author":"TJ Orchard","year":"2005","unstructured":"Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S, Fowler S, Diabetes Prevention Program Research G: The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial.[see comment][summary for patients in Ann Intern Med. 2005 Apr 19;142(8):I46; PMID: 15838061]. Annals of Internal Medicine. 2005, 142 (8): 611-619.","journal-title":"Annals of Internal Medicine"},{"issue":"9","key":"1163_CR19","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1056\/NEJM199602293340906","volume":"334","author":"CJ Bailey","year":"1996","unstructured":"Bailey CJ, Turner RC: Metformin. N Engl J Med. 1996, 334 (9): 574-579. 10.1056\/NEJM199602293340906.","journal-title":"N Engl J Med"},{"issue":"1","key":"1163_CR20","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/sj.ijo.0803695","volume":"32","author":"A Golay","year":"2008","unstructured":"Golay A: Metformin and body weight. International Journal of Obesity. 2008, 32 (1): 61-72. 10.1038\/sj.ijo.0803695.","journal-title":"International Journal of Obesity"},{"issue":"10","key":"1163_CR21","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1089\/apc.2008.0012","volume":"22","author":"LA Diehl","year":"2008","unstructured":"Diehl LA, Fabris BA, Barbosa DS, De Faria EC, Wiechmann SL, Carrilho AJF: Metformin increases HDL3-cholesterol and decreases subcutaneous truncal fat in nondiabetic patients with HIV-associated lipodystrophy. AIDS Patient Care & Stds. 2008, 22 (10): 779-786.","journal-title":"AIDS Patient Care & Stds"},{"key":"1163_CR22","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1172\/JCI11705","volume":"106","author":"CR Kahn","year":"2000","unstructured":"Kahn CR, Chen L, Cohen SE: Unraveling the mechanism of action of thiazolidinediones. Am Soc Clin Investig. 2000, 106: 1305-1307. 10.1172\/JCI11705.","journal-title":"Am Soc Clin Investig"},{"issue":"12","key":"1163_CR23","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1086\/593180","volume":"198","author":"C Hadigan","year":"2008","unstructured":"Hadigan C: Peroxisome proliferator-activated receptor gamma agonists and the treatment of HIV-associated lipoatrophy: unraveling the molecular mechanism of their shortcomings. Journal of Infectious Diseases. 2008, 198 (12): 1729-1731. 10.1086\/593180.","journal-title":"Journal of Infectious Diseases"},{"issue":"4","key":"1163_CR24","doi-asserted-by":"publisher","first-page":"263","DOI":"10.7326\/0003-4819-133-4-200008150-00009","volume":"133","author":"E Arioglu","year":"2000","unstructured":"Arioglu E, Duncan-Morin J, Sebring N: Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Annals of Internal Medicine. 2000, 133 (4): 263-274.","journal-title":"Annals of Internal Medicine"},{"issue":"3","key":"1163_CR25","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1345\/aph.1D081","volume":"38","author":"S Benavides","year":"2004","unstructured":"Benavides S, Nahata MC: Pharmacologic therapy for HIV-associated lipodystrophy. Annals of Pharmacotherapy. 2004, 38 (3): 448-457. 10.1345\/aph.1D081.","journal-title":"Annals of Pharmacotherapy"},{"issue":"6","key":"1163_CR26","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/j.1468-1293.2007.00480.x","volume":"8","author":"C McGoldrick","year":"2007","unstructured":"McGoldrick C, Leen CLS: The management of dyslipidaemias in antiretroviral-treated HIV infection: a systematic review. HIV Medicine. 2007, 8 (6): 325-334. 10.1111\/j.1468-1293.2007.00480.x.","journal-title":"HIV Medicine"},{"issue":"24","key":"1163_CR27","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1056\/NEJMoa072761","volume":"356","author":"SE Nissen","year":"2007","unstructured":"Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.[Erratum appears in N Engl J Med. 2007 Jul 5;357(1):100.]. New England Journal of Medicine. 2007, 356 (24): 2457-2471. 10.1056\/NEJMoa072761.","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"1163_CR28","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1093\/ije\/31.1.150","volume":"31","author":"KA Robinson","year":"2002","unstructured":"Robinson KA, Dickersin K: Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed. International Journal of Epidemiology. 2002, 31 (1): 150-153. 10.1093\/ije\/31.1.150.","journal-title":"International Journal of Epidemiology"},{"issue":"1","key":"1163_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ: Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials. 1996, 17 (1): 1-12. 10.1016\/0197-2456(95)00134-4.","journal-title":"Controlled Clinical Trials"},{"issue":"15","key":"1163_CR30","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1056\/NEJM199604113341504","volume":"334","author":"J-P Despres","year":"1996","unstructured":"Despres J-P, Lamarche B, Mauriege P, Cantin B, Dagenais GR, Moorjani S, Lupien P-J: Hyperinsulinemia as an Independent Risk Factor for Ischemic Heart Disease. N Engl J Med. 1996, 334 (15): 952-958. 10.1056\/NEJM199604113341504.","journal-title":"N Engl J Med"},{"issue":"6","key":"1163_CR31","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.soard.2007.07.013","volume":"3","author":"EH Livingston","year":"2007","unstructured":"Livingston EH, Chandalia M, Abate N: Do current body mass index criteria for obesity surgery reflect cardiovascular risk?. Surgery for Obesity & Related Diseases. 2007, 3 (6): 577-585.","journal-title":"Surgery for Obesity & Related Diseases"},{"issue":"3","key":"1163_CR32","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/ajcn\/74.3.315","volume":"74","author":"JC Seidell","year":"2001","unstructured":"Seidell JC, Perusse L, Despres JP, Bouchard C: Waist and hip circumferences have independent and opposite effects on cardiovascular disease risk factors: the Quebec Family Study. American Journal of Clinical Nutrition. 2001, 74 (3): 315-321.","journal-title":"American Journal of Clinical Nutrition"},{"key":"1163_CR33","volume-title":"The Cochrane Collaboration","author":"J Higgins","year":"2008","unstructured":"Higgins J, Green S: Cochrane Handbook for Systematic Reviews of Interventions, vol. 5.0.1. The Cochrane Collaboration. 2008"},{"issue":"5","key":"1163_CR34","doi-asserted-by":"publisher","first-page":"337","DOI":"10.7326\/0003-4819-143-5-200509060-00009","volume":"143","author":"JPH van Wijk","year":"2005","unstructured":"van Wijk JPH, de Koning EJP, Cabezas MC, op't Roodt J, Joven J, Rabelink TJ, Hoepelman AI: Comparison of rosiglitazone and metformin for treating HIV lipodystrophy: a randomized trial.[erratum appears in Ann Intern Med. 2005 Nov 1;143(9):695 Note: dosage error in text][summary for patients in Ann Intern Med. 2005 Sep 6;143(5):I38; PMID: 16144888]. Annals of Internal Medicine. 2005, 143 (5): 337-346.","journal-title":"Annals of Internal Medicine"},{"issue":"1","key":"1163_CR35","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/QAD.0b013e328011220e","volume":"21","author":"K Mulligan","year":"2007","unstructured":"Mulligan K, Yang Y, Wininger DA, Koletar SL, Parker RA, Alston-Smith BL, Schouten JT, Fielding RA, Basar MT, Grinspoon S: Effects of metformin and rosiglitazone in HIV-infected patients with hyperinsulinemia and elevated waist\/hip ratio. AIDS. 2007, 21 (1): 47-57. 10.1097\/QAD.0b013e328011220e.","journal-title":"AIDS"},{"issue":"9407","key":"1163_CR36","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/S0140-6736(04)15489-5","volume":"363","author":"A Carr","year":"2004","unstructured":"Carr A, Workman C, Carey D, Rogers G, Martin A, Baker D, Wand H, Law M, Samaras K, Emery S, et al: No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial.[see comment]. Lancet. 2004, 363 (9407): 429-438. 10.1016\/S0140-6736(04)15489-5.","journal-title":"Lancet"},{"issue":"12","key":"1163_CR37","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1086\/518005","volume":"195","author":"RB Cavalcanti","year":"2007","unstructured":"Cavalcanti RB, Raboud J, Shen S, Kain KC, Cheung A, Walmsley S: A randomized, placebo-controlled trial of rosiglitazone for HIV-related lipoatrophy.[see comment]. Journal of Infectious Diseases. 2007, 195 (12): 1754-1761. 10.1086\/518005.","journal-title":"Journal of Infectious Diseases"},{"issue":"1-3","key":"1163_CR38","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ejphar.2006.06.014","volume":"544","author":"B Coll","year":"2006","unstructured":"Coll B, van Wijk JPH, Parra S, Castro Cabezas M, Hoepelman IM, Alonso-Villaverde C, de Koning EJP, Camps J, Ferre N, Rabelink TJ, et al: Effects of rosiglitazone and metformin on postprandial paraoxonase-1 and monocyte chemoattractant protein-1 in human immunodeficiency virus-infected patients with lipodystrophy. European Journal of Pharmacology. 2006, 544 (1-3): 104-110. 10.1016\/j.ejphar.2006.06.014.","journal-title":"European Journal of Pharmacology"},{"issue":"5","key":"1163_CR39","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1086\/427697","volume":"40","author":"A Gavrila","year":"2005","unstructured":"Gavrila A, Hsu W, Tsiodras S, Doweiko J, Gautam S, Martin L, Moses AC, Karchmer AW, Mantzoros CS: Improvement in highly active antiretroviral therapy-induced metabolic syndrome by treatment with pioglitazone but not with fenofibrate: a 2 \u00d7 2 factorial, randomized, double-blinded, placebo-controlled trial. Clinical Infectious Diseases. 2005, 40 (5): 745-749. 10.1086\/427697.","journal-title":"Clinical Infectious Diseases"},{"issue":"4","key":"1163_CR40","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1001\/jama.284.4.472","volume":"284","author":"C Hadigan","year":"2000","unstructured":"Hadigan C, Corcoran C, Basgoz N, Davis B, Sax P, Grinspoon S: Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial. JAMA. 2000, 284 (4): 472-477. 10.1001\/jama.284.4.472.","journal-title":"JAMA"},{"issue":"10","key":"1163_CR41","doi-asserted-by":"publisher","first-page":"786","DOI":"10.7326\/0003-4819-140-10-200405180-00008","volume":"140","author":"C Hadigan","year":"2004","unstructured":"Hadigan C, Yawetz S, Thomas A, Havers F, Sax PE, Grinspoon S: Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial.[see comment]. Annals of Internal Medicine. 2004, 140 (10): 786-794.","journal-title":"Annals of Internal Medicine"},{"issue":"4","key":"1163_CR42","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/sj.clpt.6100047","volume":"81","author":"DG Haider","year":"2007","unstructured":"Haider DG, Schindler K, Mittermayer F, Muller M, Nowotny P, Rieger A, Luger A, Ludvik B, Wolzt M: Effect of rosiglitazone on visfatin and retinol-binding protein-4 plasma concentrations in HIV-positive patients.[erratum appears in Clin Pharmacol Ther. 2007 Apr;81(4):611]. Clinical Pharmacology & Therapeutics. 2007, 81 (4): 580-585.","journal-title":"Clinical Pharmacology & Therapeutics"},{"issue":"7","key":"1163_CR43","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/j.1468-1293.2007.00488.x","volume":"8","author":"R Kohli","year":"2007","unstructured":"Kohli R, Shevitz A, Gorbach S, Wanke C: A randomized placebo-controlled trial of metformin for the treatment of HIV lipodystrophy. HIV Medicine. 2007, 8 (7): 420-426. 10.1111\/j.1468-1293.2007.00488.x.","journal-title":"HIV Medicine"},{"issue":"1","key":"1163_CR44","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1177\/135965350501000113","volume":"10","author":"JC Kovacic","year":"2005","unstructured":"Kovacic JC, Martin A, Carey D, Wand H, Mallon PWG, Feneley MP, Emery S, Cooper DA, Carr A, Investigators R: Influence of rosiglitazone on flow-mediated dilation and other markers of cardiovascular risk in HIV-infected patients with lipoatrophy. Antiviral Therapy. 2005, 10 (1): 135-143.","journal-title":"Antiviral Therapy"},{"issue":"5","key":"1163_CR45","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1177\/135965350300800507","volume":"8","author":"E Martinez","year":"2003","unstructured":"Martinez E, Domingo P, Ribera E, Milinkovic A, Arroyo JA, Conget I, Perez-Cuevas JB, Casamitjana R, de Lazzari E, Bianchi L, et al: Effects of metformin or gemfibrozil on the lipodystrophy of HIV-infected patients receiving protease inhibitors. Antiviral Therapy. 2003, 8 (5): 403-410.","journal-title":"Antiviral Therapy"},{"issue":"8","key":"1163_CR46","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1097\/00002030-199905280-00023","volume":"13","author":"T Saint-Marc","year":"1999","unstructured":"Saint-Marc T, Touraine JL: Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor therapy. AIDS. 1999, 13 (8): 1000-1002. 10.1097\/00002030-199905280-00023.","journal-title":"AIDS"},{"issue":"6","key":"1163_CR47","doi-asserted-by":"publisher","first-page":"791","DOI":"10.3325\/cmj.2007.6.791","volume":"48","author":"A Silic","year":"2007","unstructured":"Silic A, Janez A, Tomazic J, Karner P, Vidmar L, Sharma P, Maticic M: Effect of rosiglitazone and metformin on insulin resistance in patients infected with human immunodeficiency virus receiving highly active antiretroviral therapy containing protease inhibitor: randomized prospective controlled clinical trial. Croatian Medical Journal. 2007, 48 (6): 791-799. 10.3325\/cmj.2007.6.791.","journal-title":"Croatian Medical Journal"},{"issue":"3","key":"1163_CR48","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1177\/135965350300800303","volume":"8","author":"J Sutinen","year":"2003","unstructured":"Sutinen J, Hakkinen A-M, Westerbacka J, Seppala-Lindroos A, Vehkavaara S, Halavaara J, Jarvinen A, Ristola M, Yki-Jarvinen H: Rosiglitazone in the treatment of HAART-associated lipodystrophy--a randomized double-blind placebo-controlled study. Antiviral Therapy. 2003, 8 (3): 199-207.","journal-title":"Antiviral Therapy"},{"issue":"3","key":"1163_CR49","first-page":"99","volume":"14","author":"J Tomazic","year":"2005","unstructured":"Tomazic J, Karner P, Vidmar L, Maticic M, Sharma PM, Janez A: Effect of metformin and rosiglitazone on lipid metabolism in HIV infected patients receiving protease inhibitor containing HAART. Acta Dermatovenerologica Alpina, Panonica et Adriatica. 2005, 14 (3): 99-105.","journal-title":"Acta Dermatovenerologica Alpina, Panonica et Adriatica"},{"issue":"4","key":"1163_CR50","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1161\/01.ATV.0000062885.61917.A5","volume":"23","author":"H Yki-Jarvinen","year":"2003","unstructured":"Yki-Jarvinen H, Sutinen J, Silveira A, Korsheninnikova E, Fisher RM, Kannisto K, Ehrenborg E, Eriksson P, Hamsten A: Regulation of plasma PAI-1 concentrations in HAART-associated lipodystrophy during rosiglitazone therapy. Arteriosclerosis, Thrombosis & Vascular Biology. 2003, 23 (4): 688-694.","journal-title":"Arteriosclerosis, Thrombosis & Vascular Biology"},{"issue":"1","key":"1163_CR51","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/135965350801300107","volume":"13","author":"L Slama","year":"2008","unstructured":"Slama L, Lanoy E, Valantin M-A, Bastard J-P, Chermak A, Boutekatjirt A, William-Faltaos D, Billaud E, Molina J-M, Capeau J, et al: Effect of pioglitazone on HIV-1-related lipodystrophy: a randomized double-blind placebo-controlled trial (ANRS 113). Antiviral Therapy. 2008, 13 (1): 67-76.","journal-title":"Antiviral Therapy"},{"key":"1163_CR52","doi-asserted-by":"publisher","first-page":"E1097","DOI":"10.1152\/ajpendo.90988.2008","volume":"297","author":"R Blumer","year":"2009","unstructured":"Blumer R, van der Valk M, Achermans M, Endert E, Serlie M, Reiss P, Sauerwein H: A rosiglitazone-induced increase in adiponectin does not improve glucose metabolism in HIV-infected patients with overt lipoatrophy. Am J Physiol Endocrinol Metab. 2009, 297: E1097-E1104. 10.1152\/ajpendo.90988.2008.","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"7","key":"1163_CR53","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1055\/s-0029-1202779","volume":"41","author":"K Schindler","year":"2009","unstructured":"Schindler K, Rieger A, Tura A, Gmeinhardt B, Touzeau-Romer V, Haider D, Pacini G, Ludvik B, Schindler K, Rieger A, et al: The effect of rosiglitazone on insulin sensitivity, beta cell function, bone mineral density, and body composition in hiv-positive patients on highly-active antiretroviral therapy (HAART). Hormone & Metabolic Research. 2009, 41 (7): 573-579.","journal-title":"Hormone & Metabolic Research"},{"key":"1163_CR54","volume-title":"Combination of Insulin Sensitizer and Leptin as Treatment for HAART-Inducted Metabolic Syndrome","author":"C Mantzoros","year":"2008","unstructured":"Mantzoros C, Brennan A: Combination of Insulin Sensitizer and Leptin as Treatment for HAART-Inducted Metabolic Syndrome. 2008, Boston: Beth Isreal Deaconess Medical Center, ClinicalTrials.gov identifier: NCT00362440"},{"key":"1163_CR55","volume-title":"Myocardial Function and FFA Metabolism in HIV Metabolic Syndrome","author":"S Lassa-Claxton","year":"2010","unstructured":"Lassa-Claxton S, Cade T, Yarasheski K: Myocardial Function and FFA Metabolism in HIV Metabolic Syndrome. 2010, St. Louis: Washington University School of Medicine, ClinicalTrials.gov identifier: NCT00656851"},{"key":"1163_CR56","volume-title":"Exercise and Pioglitazone for HIV-Metabolic Syndromes","author":"S Lassa-Claxton","year":"2009","unstructured":"Lassa-Claxton S, Laciny E, Yarasheski K: Exercise and Pioglitazone for HIV-Metabolic Syndromes. 2009, St. Louis: National Institute of Diabetes and Digestions, ClinicalTrials.gov identifier: NCT00639457"},{"issue":"4","key":"1163_CR57","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1177\/135965350300800412","volume":"8","author":"M Galli","year":"2003","unstructured":"Galli M, Ridolfo AL, Adorni F, Cappelletti A, Morelli P, Massetto B, Piazza M, Gianelli E, Vaccarezza M, Gervasoni C, et al: Correlates of risk of adipose tissue alterations and their modifications over time in HIV-1-infected women treated with antiretroviral therapy. Antiviral Therapy. 2003, 8 (4): 347-354.","journal-title":"Antiviral Therapy"},{"issue":"10","key":"1163_CR58","doi-asserted-by":"publisher","first-page":"4611","DOI":"10.1210\/jc.2002-020709","volume":"87","author":"C Hadigan","year":"2002","unstructured":"Hadigan C, Rabe J, Grinspoon S: Sustained benefits of metformin therapy on markers of cardiovascular risk in human immunodeficiency virus-infected patients with fat redistribution and insulin resistance. Journal of Clinical Endocrinology & Metabolism. 2002, 87 (10): 4611-4615.","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"issue":"1","key":"1163_CR59","doi-asserted-by":"publisher","first-page":"193","DOI":"10.2337\/dc08-9025","volume":"32","author":"DM Nathan","year":"2009","unstructured":"Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B: Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009, 32 (1): 193-203. 10.2337\/dc08-9025.","journal-title":"Diabetes Care"},{"issue":"2","key":"1163_CR60","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.amjmed.2007.09.016","volume":"121","author":"SR Salpeter","year":"2008","unstructured":"Salpeter SR, Buckley NS, Kahn JA, Salpeter EE, Salpeter SR, Buckley NS, Kahn JA, Salpeter EE: Meta-analysis: metformin treatment in persons at risk for diabetes mellitus.[see comment]. American Journal of Medicine. 2008, 121 (2): 149-157. 10.1016\/j.amjmed.2007.09.016. e142","journal-title":"American Journal of Medicine"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2334-10-183\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-10-183.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-10-183","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-10-183.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T18:41:39Z","timestamp":1685644899000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/1471-2334-10-183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,23]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["1163"],"URL":"https:\/\/doi.org\/10.1186\/1471-2334-10-183","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,23]]},"article-number":"183"}}